Cheap, toxic and easily accessible, a ‘new’ street substance known as suck-and-die is fast gaining notoriety among the youth. Marketed in secrecy and ...

Aquestive Therapeutics (NASDAQ:AQST), a biopharmaceutical company specializing in orally administered therapeutics, is garnering attention from investors and analysts alike as it approaches a critical ...

In September 2025, analysts highlighted that the FDA waived the advisory committee meeting for Aquestive Therapeutics’ New Drug Application for Anaphylm, a needle-free, orally delivered epinephrine ...

neffy 1 mg and 2 mg doses approved by Japanese regulators neffy offers a new delivery method for epinephrine in Japan for adults and children (>15 kg) living with severe allergic reactions Alfresa ...

Significant respiratory improvements were seen as early as week 4 with dexpramipexole 150mg taken twice daily. Topline data were announced from a phase 3 trial evaluating dexpramipexole as an add-on ...

Enbumyst, a bumetanide nasal spray, is FDA-approved for edema in CHF, hepatic, and renal diseases, offering outpatient treatment. The nasal spray bridges gaps between oral and IV diuretics, providing ...

Areteia Therapeutics, Inc. (“Areteia”) today announced positive results from the Phase III EXHALE-4 efficacy and safety study of dexpramipexole as an add-on oral therapy in participants with ...

Choi Ha-young, a professor of respiratory medicine at Hallym University Gangnam Sacred Heart Hospital (Hospital Director Lee Dong-jin), has been selected as the '2025 Glocal R&D Support Project' among ...